Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report released on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Down 6.6 %

Shares of Akari Therapeutics stock opened at $0.99 on Friday. The business’s 50-day moving average price is $1.15 and its 200-day moving average price is $2.11. Akari Therapeutics has a 12 month low of $0.90 and a 12 month high of $4.40.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.